✓ During a period of 3 years, 25 patients with intra- and extrasellar macroprolactinomas were pretreated with dopamine agonists for a period of 2 to 6½ weeks prior to transsphenoidal microsurgical tumor resection. Dopamine agonists were administered orally to 17 patients, intramuscularly to three patients, and both orally and intramuscularly to five patients. Repeated computerized tomography (CT) examinations revealed that all neoplasms except one cystic tumor were reduced in size during the course of dopamine-agonist administration. No complications attributable to medical pretreatment were observed. Tumor shrinkage increased the efficacy of surgery, especially in cases with considerable extrasellar extension of the adenomas. Within 3 months following adenomectomy, prolactin levels were adjusted to normal levels in 19 patients by additional low-dose treatment with dopamine agonists. Thin-collimation CT assessments performed at least 3 months after surgery showed no evidence of residual tumor tissue in 23 patients. It is concluded that administration of dopamine agonists for some weeks prior to surgery is a useful adjunct to transsphenoidal microsurgery for macroprolactinomas. The new injectable form of bromocriptine is particularly valuable for this purpose.
Barrow DL, , Tindall GT, & Kovacs K, et al: Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg 60:1–7, 1984 Barrow DL, Tindall GT, Kovacs K, et al: Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg 60:1–7, 1984
Breidahl HD, , Topliss DJ, & Pike JW: Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br Med J 287:451–452, 1983 Breidahl HD, Topliss DJ, Pike JW: Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br Med J 287:451–452, 1983
Chiodini PG, , Liuzzi A, & Cozzi R, et al: Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab 53:737–743, 1982 Chiodini PG, Liuzzi A, Cozzi R, et al: Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab 53:737–743, 1982
Clayton RN, , Webb J, & Heath DA, et al: Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: a case report. Clin Endocrinol 22:573–581, 1985 Clayton RN, Webb J, Heath DA, et al: Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: a case report. Clin Endocrinol 22:573–581, 1985
Corenblum B: Bromocriptine in pituitary tumours. Lancet 2:786, 1978 (Letter) Corenblum B: Bromocriptine in pituitary tumours. Lancet 2:786, 1978 (Letter)
Derome PJ, , Peillon F, & Bard RH, et al: Adénomes á prolactine: résultats du traitement chirurgical. 120 cas féminins, 30 cas masculins. Nouv Presse Med 8:577–583, 1979 Derome PJ, Peillon F, Bard RH, et al: Adénomes á prolactine: résultats du traitement chirurgical. 120 cas féminins, 30 cas masculins. Nouv Presse Med 8:577–583, 1979
Desaga U, , Lüdecke D, & Kühne D: Prolactin lowering effect of Lisuride and reduction of tumor size in patients with prolactinomas. Period Biol 85 (Suppl l): 73–82, 1983 Desaga U, Lüdecke D, Kühne D: Prolactin lowering effect of Lisuride and reduction of tumor size in patients with prolactinomas. Period Biol 85 (Suppl l):73–82, 1983
Eversmann T, , Fahlbusch R, & Rjosk HK, et al: Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol 92:413–427, 1979 Eversmann T, Fahlbusch R, Rjosk HK, et al: Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol 92:413–427, 1979
Fahlbusch R: Surgical failures in prolactinomas, in Derome PJ, , Jedynak CP, & Peillon F (eds): Pituitary Adenomas. Biology, Pathology, and Treatment. Paris: Asclepios, 1980, pp 273–284 Fahlbusch R: Surgical failures in prolactinomas, in Derome PJ, Jedynak CP, Peillon F (eds): Pituitary Adenomas. Biology, Pathology, and Treatment. Paris: Asclepios, 1980, pp 273–284
Fahlbusch R, & Buchfelder M: Present status of neurosurgery in the treatment of prolactinomas. Neurosurg Rev 8:195–205, 1985 Fahlbusch R, Buchfelder M: Present status of neurosurgery in the treatment of prolactinomas. Neurosurg Rev 8:195–205, 1985
Faria MA, & Tindall GT: Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. Results in 100 women with the amenorrhea-galactorrhea syndrome. J Neurosurg 56:33–43, 1982 Faria MA, Tindall GT: Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. Results in 100 women with the amenorrhea-galactorrhea syndrome. J Neurosurg 56:33–43, 1982
Gen M, , Uozumi T, & Ohta M, et al: Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab 59:463–470, 1984 Gen M, Uozumi T, Ohta M, et al: Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab 59:463–470, 1984
George SR, , Burrow GN, & Zinman B, et al: Regression of pituitary tumors, a possible effect of bromergocryptine. Am J Med 66:697–702, 1979 George SR, Burrow GN, Zinman B, et al: Regression of pituitary tumors, a possible effect of bromergocryptine. Am J Med 66:697–702, 1979
Grossman A, & Besser GM: Prolactinomas. Br Med J 290:182–184, 1985 Grossman A, Besser GM: Prolactinomas. Br Med J 290:182–184, 1985
Grossman A, , Ross R, & Wass JAH, et al: Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin Endocrinol 24:231–238, 1986 Grossman A, Ross R, Wass JAH, et al: Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin Endocrinol 24:231–238, 1986
Hardy J, & Mohr G: Le prolactinome. Aspects chirurgicaux. Neurochirurgie 27 (Suppl l): 41–60, 1981 Hardy J, Mohr G: Le prolactinome. Aspects chirurgicaux. Neurochirurgie 27 (Suppl l):41–60, 1981
Kendall-Taylor P, , Hall K, & Johnston DG, et al: Reduction in size of prolactin-secreting tumours in men treated with pergolide. Br Med J 285:465–467, 1982 Kendall-Taylor P, Hall K, Johnston DG, et al: Reduction in size of prolactin-secreting tumours in men treated with pergolide. Br Med J 285:465–467, 1982
Landolt AM, , del Pozo E, & Hajek J: Injectable bromocriptine to treat acute, oestrogen-induced swelling of invasive prolactinoma. Lancet 2:111–1984 (Letter) Landolt AM, del Pozo E, Hajek J: Injectable bromocriptine to treat acute, oestrogen-induced swelling of invasive prolactinoma. Lancet 2:111, 1984 (Letter)
Landolt AM, & Osterwalder V: Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58:1179–1183, 1984 Landolt AM, Osterwalder V: Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58:1179–1183, 1984
Liuzzi A, , Dallabonzana D, & Oppizzi G, et al: Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313:656–659, 1985 Liuzzi A, Dallabonzana D, Oppizzi G, et al: Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313:656–659, 1985
MacLeod RM, & Lehmeyer JE: Suppression of pituitary tumor growth and function by ergot alkaloids. Cancer Res 33:849–855, 1973 MacLeod RM, Lehmeyer JE: Suppression of pituitary tumor growth and function by ergot alkaloids. Cancer Res 33:849–855, 1973
Molitch ME, , Elton RL, & Blackwell RE, et al: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705, 1985 Molitch ME, Elton RL, Blackwell RE, et al: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705, 1985
Nissim M, , Ambrosi B, & Bernasconi V, et al: Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. J Endocrinol Invest 5:409–415, 1982 Nissim M, Ambrosi B, Bernasconi V, et al: Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. J Endocrinol Invest 5:409–415, 1982
Rengachary SS, , Tomita T, & Jefferies BF, et al: Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242–251, 1982 Rengachary SS, Tomita T, Jefferies BF, et al: Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242–251, 1982
Sobrinho LG, , Nunes MC, & Calhaz-Jorge C, et al: Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours. Acta Endocrinol 96:24–29, 1981 Sobrinho LG, Nunes MC, Calhaz-Jorge C, et al: Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours. Acta Endocrinol 96:24–29, 1981
Sobrinho LG, , Nunes MC, & Santos MA, et al: Radiological evidence for regression of prolactinoma after treatment with bromocriptine. Lancet 2:257–258, 1978 (Letter) Sobrinho LG, Nunes MC, Santos MA, et al: Radiological evidence for regression of prolactinoma after treatment with bromocriptine. Lancet 2:257–258, 1978 (Letter)
Thorner MO, , Martin WH, & Rogol AD, et al: Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 51:438–445, 1980 Thorner MO, Martin WH, Rogol AD, et al: Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 51:438–445, 1980
Thorner MO, , Perryman RL, & Rogol AD, et al: Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 53:480–483, 1981 Thorner MO, Perryman RL, Rogol AD, et al: Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 53:480–483, 1981
Tindall GT, , Kovacs K, & Horvath E, et al: Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178–1183, 1982 Tindall GT, Kovacs K, Horvath E, et al: Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178–1183, 1982
Vaidya RA, , Aloorkar SD, & Rege NR, et al: Normalization of visual fields following bromocriptine treatment in hyperprolactinemic patients with visual field constriction. Fertil Steril 29:632–636, 1978 Vaidya RA, Aloorkar SD, Rege NR, et al: Normalization of visual fields following bromocriptine treatment in hyperprolactinemic patients with visual field constriction. Fertil Steril 29:632–636, 1978
Von Werder K, , Landgraf R, & Müller OA, et al: Treatment of hyperprolactinaemia with the new dopamine-agonist mesulergine (CU 32-085), in McLeod RM, , Thorner MO, & Scapagnini U (eds): Prolactin. Basic and Clinical Considerations. Padova: Liviana, 1985, pp 787–794 Von Werder K, Landgraf R, Müller OA, et al: Treatment of hyperprolactinaemia with the new dopamine-agonist mesulergine (CU 32-085), in McLeod RM, Thorner MO, Scapagnini U (eds): Prolactin. Basic and Clinical Considerations. Padova: Liviana, 1985, pp 787–794
Wass JAH, , Moult PJA, & Thorner MO, et al: Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 2:66–69, 1979 Wass JAH, Moult PJA, Thorner MO, et al: Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 2:66–69, 1979
Weiss MH, , Wycoft RR, & Yadley R, et al: Bromocriptine treatment of prolactin-secreting tumors: surgical implications. Neurosurgery 12:640–642, 1983 Weiss MH, Wycoft RR, Yadley R, et al: Bromocriptine treatment of prolactin-secreting tumors: surgical implications. Neurosurgery 12:640–642, 1983
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 245 | 46 | 9 |
| Full Text Views | 145 | 0 | 0 |
| PDF Downloads | 113 | 0 | 0 |
| EPUB Downloads | 0 | 0 | 0 |